Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session ... Meanwhile, the Dow lost 0.28%, and the Nasdaq, a tech-heavy index, lost 1.2%. Prior to today's trading, shares of the drugmaker ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.

Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 80% showed bearish ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...

CPI Readings Due in U.S. Next Week Monday U.S. Featured Earnings McDonalds (NYSE:MCD) (Q4) EPS of $2.82 compared to $2.95 in ...

Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is soon expected to post earnings of $3.99 per share for the quarter ended December 2024.

VRTX is scheduled to release results on Feb. 10, after market close. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...